JERUSALEM, May 11, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”, or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced groundbreaking interim data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial.
Read more here.
![[Bizzabo on Get Down To Business with Shalom Klein] Alon Alroy with Shalom Klein on Get Down To Business](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
